GSK: priority review in China for multiple myeloma

(CercleFinance.com) - GSK announces that China's National Medical Products Administration (NMPA) has accepted for review the application for approval of Blenrep (belantamab mafodotine) in combination with bortezomib and dexamethasone (BVd) to treat relapsed or refractory multiple myeloma.


This application benefits from priority review and breakthrough therapy status to accelerate its development.

This approval is based on the results of two clinical trials showing significant improvements in progression-free survival and overall survival compared with standard treatments.

In 2024, seven similar applications were filed in other major markets, including the US, the EU, Japan and Canada.


Copyright (c) 2024 CercleFinance.com. All rights reserved.